Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (Q36352827)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Leena Gandhi

3

0 references

object named as

David C Smith

12

0 references

19

object named as

Mario Sznol

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

17

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lecia V Sequist

11

object named as

Lecia V Sequist

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Suzanne L. Topalian

16

object named as

Suzanne L Topalian

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

21

object named as

Drew M Pardoll

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Scott N Gettinger

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Leora Horn

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David R Spigel

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Scott J Antonia

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Naiyer A Rizvi

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

John D Powderly

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Rebecca S Heist

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Richard D Carvajal

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David M Jackman

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Philip Leming

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David P Carbone

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Mary C Pinder-Schenck

15

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jeffrey A Sosman

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David F McDermott

20

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Vindira Sankar

22

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Christoph M Ahlers

23

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Mark Salvati

24

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jon M Wigginton

25

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Matthew D Hellmann

26

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Georgia D Kollia

27

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ashok K Gupta

28

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Julie R Brahmer

29

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

20 April 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

33

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

2004-2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

A decade of advances in treatment for advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

30 September 2017

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

22 September 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

22 September 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4672027

22 September 2018

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25897158

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2014.58.3708

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36352827&oldid=1906283832"